Professor Hao is wearing glasses, a suit and tie, and has a gentle and amiable face.

Two assistants next to him brought computers to help show the ppt content of the lecture.

"Dear colleagues, today I will give you some of the latest research progress on PTCD endotracheal radiotherapy. This is a technology introduced from abroad. It has been developing in our country for more than ten years. It is a technology that is not widely used in China but is relatively mature. The technology we use in China is basically the source of iridium 192 wire entering the bile catheter for wire source. As for the location where it is placed, the distance from the tumor, these require more detailed research. Our hospital has been doing this technology for more than eight years, so I have some experience with my colleagues to share it with my colleagues."

Although he is a professor, he is very modest in discussing academic issues, and speaks calmly and brings a lot of scholarly spirit.

The audience was basically silent, and they were all studying quietly on the screen.

"Chasic duct cancer is actually not very sensitive to chemotherapy. This technology is not used first. However, after being used in clinical practice, there are many happier discoveries. For example, if the tumor is less than 1.5 cm, you can only use intraluminal irradiation, and the survival period can be longer. Tumors larger than 1.5 cm are best added with external irradiation. In any case, it is definitely much better than pure external irradiation. The survival period of patients can be relatively extended."

I guess I felt a little bored in the conference room as I was talking. Professor Hao adjusted the atmosphere on the spot and said to the audience: "If you have any ideas or suggestions from colleagues, you can ask questions and speak at any time. We can see it with your hand."

When someone heard him say this, he raised his hand.

The assistant immediately handed the microphone over to the man.

"Doctor Hao, is this technology only used in palliative care? Our hospital once wanted to try to apply it before and after the operation. I don't know if your hospital has tried this practice and research. I want to know if it is meaningful for tumor reduction before surgery and to remove residual tumor tissue after surgery? We have read relevant papers, and some colleagues have done similar research, but for some reason there are very few cases. Can Professor Hao answer relevant questions?"

The doctor asked this question a series of questions, all of which were practical questions full of practical information, which showed that he was definitely a front-line doctor.

Professor Hao smiled and asked the other party to sit down and explained: "About the questions you mentioned, especially the last question, why are there less pre- and post-operative applications. It is mainly because we have more than one technology to reduce tumors before and after surgery and remove residual tumor tissue after surgery. Compared with other technologies, I said at the beginning that cholangiocarcinoma has a relatively low sensitivity to radiotherapy. With advanced chemotherapy drugs, we can certainly use chemotherapy drugs to reduce tumors and remove residual tumor tissue. This technology can only be said to have certain advantages in palliative therapy, which is that it can eliminate tumors locally. If there are more advanced drugs in the future, there will be no need to maintain drainage."

After the experts finished speaking, the front-line doctors at the grassroots level were inspired and stood up and said thank you again.
Chapter completed!